PDF bertilimumab.pdf | Request a copy Full text restricted Available under University of Tasmania Standard License.

Abstract

Cambridge Antibody Technology (CAT) is developing
bertilimumab, an anti-eotaxin-1 monoclonal antibody, for the potential treatment of allergic disorders. By September 2003, CAT had released results from phase I/II trials, and was seeking to outlicense rights for bertilimumab.

Item Type:	Article
Authors/Creators:	Ding, C and Li, J and Zhang, X
Journal or Publication Title:	Current Opinion in Investigational Drugs
ISSN:	1472-4472
Item Statistics:	View statistics for this item

Actions (login required)

Item Control Page